Description

Advanced Glycation End Products (AGEs; also termed as glycotoxins) are a group of heterogeneous compounds formed through non-enzymatic glycation and oxidization processes between reducing sugars and protein side chains, lipids, or nucleic acids. Initial glycation and oxidation processes usually form Schiff bases and Amadori products. Glycation itself causes molecular rearrangements that lead to the generation of AGEs. The formation of these molecules is part of normal metabolism; however, under certain pathological conditions, such as oxidative stress, the production of AGEs can be abnormally excessive, leading to pathogenic conditions. The formation and accumulation of AGEs have been implicated in aging and in the development of many degenerative diseases, such as diabetes, chronic kidney disease, atherosclerosis and Alzheimer’s disease. By definition, there is not a universally accepted method to measure or quantify AGEs due to their heterogeneity. Nevertheless, since most AGEs have intrinsic fluorescence, measurements of AGE-specific fluorescence may serve as a simple and useful test to monitor circulating AGEs levels and monitor AGEs excretion. BioVision’s Advanced Glycation End Products (AGEs) Assay Kit is a 96-well microplate-based assay that can be used for the semi-quantitative estimation of fluorescent AGEs levels in Biological Fluids. The assay is based on the characteristic fluorescence (Ex/Em= 360/460 nm), a characteristic that is shared by almost all AGEs. The proprietary composition of the Assay Buffer specifically distinguishes between AGEs and non-oxidized proteins. The one-step assay uses oxidized Bovine Serum Albumin (AGE-BSA) as a Positive Control. BSA is used as Background Control and its fluorescence under assay conditions is defined as 1 relative fluorescence intensity in arbitrary units (AU or RFUSample/ RFUBackground).

Datasheet

FAQ

-

CITATIONS
Mohamed M. Elshemy. Antioxidative Capacity of Liver- and Adipose-Derived Mesenchymal Stem Cell-Conditioned Media and Their Applicability in Treatment of Type 2 Diabetic Rats. Oxid Med Cell Longev. Feb 2021. 33623636.

Downloads